|
Stomach Neoplasms
|
0.020 |
AlteredExpression
|
group |
LHGDN |
Expression profile of histone deacetylase 1 in gastric cancer tissues.
|
11749695 |
2001 |
|
Stomach Neoplasms
|
0.020 |
AlteredExpression
|
group |
LHGDN |
DNA methylation and histone deacetylation associated with silencing DAP kinase gene expression in colorectal and gastric cancers.
|
12087472 |
2002 |
|
Stomach Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
RNA-seq data from The Cancer Genome Atlas revealed that expression of B7-H1, HDAC1-3, 6-8, and 10 and SIRT1, 3, 5, and 6 was higher, and expression of HDAC5 and SIRT4 was lower in GC compared to that in normal gastric tissues; that HDAC3 and HDAC1 expression level significantly correlated with B7-H1 in GC with a respective r value of 0.42 (p < 0.001) and 0.21 (p < 0.001).
|
30537988 |
2018 |
|
Stomach Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Histone deacetylase 1 expression in gastric cancer.
|
21725604 |
2011 |
|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, results of the present study indicated that HDAC1 depletion inhibits the metastatic abilities of gastric cancer cells by regulating the miRNA-34a/CD44 pathway, which may be a potential target for the treatment of gastric cancer.
|
26035691 |
2015 |
|
Stomach Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Thus, the present study clearly demonstrates that HDAC1 is overexpressed in GC and probably plays a significant role in gastric carcinogenesis.
|
11749695 |
2001 |
|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
RTKN could work as an oncogene via regulating HDAC1/p53 and may become a promising treatment strategy for GC.
|
30774435 |
2019 |
|
Stomach Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The co-expression of MTA2 and HDAC1 in gastric cancer achieved 65.3% sensitivity (95% CI: 51.5%-79.1%) and 65.2% specificity (95% CI: 50.9%-79.5%), which was strongly associated with lymph node metastasis and TNM staging.
|
28502558 |
2017 |
|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The present study demonstrated that HDAC1 is involved in the promotion of GC cell proliferation, possibly by upregulating the expression of the lncRNAs, BC01600 and AF116637, in the tissues of patients with GC.
|
30867763 |
2019 |
|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The relationship of CD133, histone deacetylase 1 and thrombospondin-1 in gastric cancer.
|
25862862 |
2015 |
|
Stomach Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, decreased expression of HDAC5 in GC is reported for the first time in this study, while supporting the existing literature in AURKA, NEK6, HDAC1, and HDAC2 up regulations during GC development.
|
30250993 |
2018 |
|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
High HDAC1 (HDAC1<sup>High</sup>) staining was seen in 60.7% patients with GCs, which was significantly greater than was seen in normal epithelial cells (19.4%; P < .005).
|
30500418 |
2019 |
|
Steatohepatitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
The HDAC1 transgenic mice exhibited a high incidence of hepatic steatosis and nuclear pleomorphism.
|
15796905 |
2005 |
|
Status Epilepticus
|
0.010 |
Biomarker
|
disease |
BEFREE |
The coimmunoprecipitation assay revealed that the interaction between yin yang 1 and histone deacetylase 1 in the cortex and hippocampus was enhanced during SE, indicating that this interaction is also responsible for the CYP2D4 suppression.
|
29175413 |
2018 |
|
Stage IV Gallbladder Cancer AJCC v8
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
However, the expression of HDAC1 in patients with gallbladder cancer is still unknown.
|
27092878 |
2016 |
|
Stage III Gallbladder Cancer AJCC v8
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
However, the expression of HDAC1 in patients with gallbladder cancer is still unknown.
|
27092878 |
2016 |
|
Stage IIB Gallbladder Cancer AJCC v8
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
However, the expression of HDAC1 in patients with gallbladder cancer is still unknown.
|
27092878 |
2016 |
|
Stage IIA Gallbladder Cancer AJCC v8
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
However, the expression of HDAC1 in patients with gallbladder cancer is still unknown.
|
27092878 |
2016 |
|
Stage I Lung Cancer AJCC v8
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The HDAC1/GAPDH mRNA levels were significantly higher in stage III or IV lung cancer (50.929 +/- 120.433) than in stage I lung cancer (11.430 +/- 25.611, P = 0.0472).
|
15474665 |
2004 |
|
Stage I Lung Cancer AJCC v7
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The HDAC1/GAPDH mRNA levels were significantly higher in stage III or IV lung cancer (50.929 +/- 120.433) than in stage I lung cancer (11.430 +/- 25.611, P = 0.0472).
|
15474665 |
2004 |
|
Stage I Lung Cancer AJCC v6
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The HDAC1/GAPDH mRNA levels were significantly higher in stage III or IV lung cancer (50.929 +/- 120.433) than in stage I lung cancer (11.430 +/- 25.611, P = 0.0472).
|
15474665 |
2004 |
|
Stage 0 Gallbladder Cancer AJCC v8
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
However, the expression of HDAC1 in patients with gallbladder cancer is still unknown.
|
27092878 |
2016 |
|
Squamous cell carcinoma of the head and neck
|
0.010 |
Biomarker
|
disease |
BEFREE |
Downregulation of miR-874 was a frequent event in HNSCC. miR-874 acted as a tumour suppressor and directly targeted HDAC1.
|
23558898 |
2013 |
|
Squamous cell carcinoma of esophagus
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, we comprehensively assessed the anti-ESCC activity of a highly active HDAC1 inhibitor quisinostat.
|
30168013 |
2019 |
|
Squamous cell carcinoma of esophagus
|
0.020 |
Biomarker
|
disease |
BEFREE |
Taken together, HDAC1 and HDAC2 are associated with the progression of ESCC, and MS-275 hinders the progression and stemness of ESCC cells by suppressing the PI3K/Akt/mTOR pathway.
|
31120582 |
2019 |